Boston Scientific (BSX) Analysts Adjust Fair Value Estimate to $102.00, Highlighting Shifting Expectations

Boston Scientific's fair value estimate has been adjusted from $104.24 to $102.00. Analysts are tightening their assumptions on growth and execution, which feeds into the targets. Several firms, including Citi and Goldman Sachs, have kept Buy ratings while revising their models. Evercore ISI added Boston Scientific to its Tactical Outperform list. A wide group of banks have cut price targets by double-digit dollar amounts, and the company has been removed from premium lists. The FDA inspectors identified battery issues in certain Boston Scientific pacemakers, and the company issued Q1 2026 guidance for estimated net sales growth of 10.5% to 12.0% on a reported basis.